Anton Gueth - Net Worth and Insider Trading

Anton Gueth Net Worth

The estimated net worth of Anton Gueth is at least $3 Million dollars as of 2024-05-05. Anton Gueth is the Director of Antares Pharma Inc and owns about 467,577 shares of Antares Pharma Inc (ATRS) stock worth over $3 Million. Details can be seen in Anton Gueth's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Anton Gueth has not made any transactions after 2021-07-08 and currently still holds the listed stock(s).

Transaction Summary of Anton Gueth

Anton Gueth Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Anton Gueth owns 3 companies in total, including Antares Pharma Inc (ATRS) , Navidea Biopharmaceuticals Inc (NAVB) , and Spectrum Pharmaceuticals Inc (SPPI) .

Click here to see the complete history of Anton Gueth’s form 4 insider trades.

Insider Ownership Summary of Anton Gueth

Ticker	Comapny	Transaction Date	Type of Owner
ATRS	Antares Pharma Inc	2022-05-24	director
NAVB	Navidea Biopharmaceuticals Inc	2015-06-01	director
SPPI	Spectrum Pharmaceuticals Inc	2012-03-27	director

Anton Gueth Latest Holdings Summary

Anton Gueth currently owns a total of 1 stock. Anton Gueth owns 467,577 shares of Antares Pharma Inc (ATRS) as of July 8, 2021, with a value of $3 Million.

Latest Holdings of Anton Gueth

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ATRS	Antares Pharma Inc	2021-07-08	467,577	5.59	2,613,755

Holding Weightings of Anton Gueth

Anton Gueth Form 4 Trading Tracker

According to the SEC Form 4 filings, Anton Gueth has made a total of 1 transactions in Antares Pharma Inc (ATRS) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Antares Pharma Inc is the sale of 100,000 shares on July 8, 2021, which brought Anton Gueth around $429,000.

Insider Trading History of Anton Gueth

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Anton Gueth Trading Performance

GuruFocus tracks the stock performance after each of Anton Gueth's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Anton Gueth is 37.02%. GuruFocus also compares Anton Gueth's trading performance to market benchmark return within the same time period. The performance of stocks bought by Anton Gueth within 3 months outperforms 4 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Anton Gueth's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Anton Gueth

Average Return

Average return per transaction

Outperforming Transactions

3 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	15.48
Relative Return to S&P 500(%)	12.12

Anton Gueth Ownership Network

Ownership Network List of Anton Gueth

No Data

Ownership Network Relation of Anton Gueth

Anton Gueth Owned Company Details

What does Antares Pharma Inc do?

Who are the key executives at Antares Pharma Inc?

Anton Gueth is the director of Antares Pharma Inc. Other key executives at Antares Pharma Inc include See Remarks Peter C Richardson , Executive Vice President & CFO Fred M Powell , and See Remarks Peter J Graham .

Antares Pharma Inc (ATRS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Antares Pharma Inc (ATRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Antares Pharma Inc (ATRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Antares Pharma Inc (ATRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Antares Pharma Inc Insider Transactions

No Available Data

What does Navidea Biopharmaceuticals Inc do?

Who are the key executives at Navidea Biopharmaceuticals Inc?

Anton Gueth is the director of Navidea Biopharmaceuticals Inc. Other key executives at Navidea Biopharmaceuticals Inc include Chief Financial Officer Craig Dais , director & 10 percent owner Scott John K Jr. , and Chief Regulatory Officer Michel Mikhail .

Navidea Biopharmaceuticals Inc (NAVB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Navidea Biopharmaceuticals Inc (NAVB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Navidea Biopharmaceuticals Inc (NAVB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Navidea Biopharmaceuticals Inc (NAVB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Navidea Biopharmaceuticals Inc Insider Transactions

No Available Data

What does Spectrum Pharmaceuticals Inc do?

Who are the key executives at Spectrum Pharmaceuticals Inc?

Anton Gueth is the director of Spectrum Pharmaceuticals Inc. Other key executives at Spectrum Pharmaceuticals Inc include See Remarks Nora Brennan , Chief Legal Officer Keith M Mcgahan , and director & CEO & President Thomas J Riga .

Spectrum Pharmaceuticals Inc (SPPI) Insider Trades Summary

Over the past 18 months, Anton Gueth made no insider transaction in Spectrum Pharmaceuticals Inc (SPPI). Other recent insider transactions involving Spectrum Pharmaceuticals Inc (SPPI) include a net sale of 200,742 shares made by Thomas J Riga , a net sale of 110,082 shares made by Keith M Mcgahan , and a net purchase of 50,000 shares made by Jeff L Vacirca .

In summary, during the past 3 months, insiders sold 0 shares of Spectrum Pharmaceuticals Inc (SPPI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 343,211 shares of Spectrum Pharmaceuticals Inc (SPPI) were sold and 50,000 shares were bought by its insiders, resulting in a net sale of 293,211 shares.

Spectrum Pharmaceuticals Inc (SPPI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Spectrum Pharmaceuticals Inc Insider Transactions

No Available Data

Anton Gueth Mailing Address

Above is the net worth, insider trading, and ownership report for Anton Gueth. Currently GuruFocus does not have mailing address information for Anton Gueth.

Discussions on Anton Gueth

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.